4
Clinical Trials associated with Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live(Institute of Medical Biology Chinese Academy of Medical Sciences) / Not yet recruitingPhase 3IIT Ⅰ型+Ⅲ型口服脊灰减毒活疫苗(液苗/糖丸)(KMB17)与 IPV 序贯接种的抗体免疫持久性及加强免疫效果研究
[Translation] Study on the antibody immunity persistence and booster immunity effect of sequential vaccination with type Ⅰ+type Ⅲ oral attenuated live polio vaccine (liquid vaccine/sugar pill) (KMB17) and IPV
评价Ⅰ型+Ⅲ型口服脊髓灰质炎减毒活疫苗(人二倍体细胞)和Ⅰ型+Ⅲ型脊髓灰质炎减毒活疫苗糖丸(人二倍体细胞)与IPV联合序贯免疫接种的抗体免疫持久性,探索各序贯免疫程序于48月龄时开展加强免疫的合理性。
[Translation] To evaluate the antibody immunity persistence of type 1 + type 3 oral attenuated live polio vaccine (human diploid cells) and type 1 + type 3 polio vaccine sugar pills (human diploid cells) combined with IPV sequential immunization, and to explore the rationality of booster immunization at 48 months of age for each sequential immunization program.
/ Active, not recruitingPhase 3IIT 随机、盲法、平行对照试验评价双价脊髓灰质炎减毒活疫苗(人二倍体细胞)与IPV联合序贯免疫临床试验
[Translation] A randomized, blinded, parallel controlled trial to evaluate the sequential immunization of a bivalent attenuated live poliomyelitis vaccine (human diploid cells) combined with IPV
主要目标:比较2剂cIPV/sIPV+1剂tOPV(液体剂型/糖丸)与2剂cIPV/sIPV+1剂bOPV(液体剂型/糖丸)序贯接种后Ⅰ、Ⅱ、Ⅲ型脊髓灰质炎抗体阳转率和抗体水平。 次要目标:(1)比较1剂cIPV/sIPV+2剂tOPV(液体剂型/糖丸)与2剂cIPV/sIPV+1剂bOPV(液体剂型/糖丸)序贯接种后Ⅰ、Ⅱ、Ⅲ型脊髓灰质炎抗体阳转率和抗体水平。(2)评价bOPV(液体剂型/糖丸)疫苗的安全性。
[Translation] Primary objective: To compare the positive conversion rate and antibody levels of polio antibodies of types I, II, and III after sequential vaccination with 2 doses of cIPV/sIPV + 1 dose of tOPV (liquid dosage form/sugar pill) and 2 doses of cIPV/sIPV + 1 dose of bOPV (liquid dosage form/sugar pill). Secondary objectives: (1) To compare the positive conversion rate and antibody levels of polio antibodies of types I, II, and III after sequential vaccination with 1 dose of cIPV/sIPV + 2 doses of tOPV (liquid dosage form/sugar pill) and 2 doses of cIPV/sIPV + 1 dose of bOPV (liquid dosage form/sugar pill). (2) To evaluate the safety of bOPV (liquid dosage form/sugar pill) vaccine.
/ Active, not recruitingPhase 3IIT 随机、盲法、平行对照试验评价双价脊髓灰质炎减毒活疫苗(人二倍体细胞)与IPV联合序贯免疫临床试验
[Translation] A randomized, blinded, parallel controlled trial to evaluate the sequential immunization of a bivalent attenuated live poliomyelitis vaccine (human diploid cells) combined with IPV
主要目标:比较2剂cIPV/sIPV+1剂tOPV(液体剂型/糖丸)与2剂cIPV/sIPV+1剂bOPV(液体剂型/糖丸)序贯接种后Ⅰ、Ⅱ、Ⅲ型脊髓灰质炎抗体阳转率和抗体水平。 次要目标:(1)比较1剂cIPV/sIPV+2剂tOPV(液体剂型/糖丸)与2剂cIPV/sIPV+1剂bOPV(液体剂型/糖丸)序贯接种后Ⅰ、Ⅱ、Ⅲ型脊髓灰质炎抗体阳转率和抗体水平。(2)评价bOPV(液体剂型/糖丸)疫苗的安全性。
[Translation] Primary objective: To compare the positive conversion rate and antibody levels of polio antibodies of types I, II, and III after sequential vaccination with 2 doses of cIPV/sIPV + 1 dose of tOPV (liquid dosage form/sugar pill) and 2 doses of cIPV/sIPV + 1 dose of bOPV (liquid dosage form/sugar pill). Secondary objectives: (1) To compare the positive conversion rate and antibody levels of polio antibodies of types I, II, and III after sequential vaccination with 1 dose of cIPV/sIPV + 2 doses of tOPV (liquid dosage form/sugar pill) and 2 doses of cIPV/sIPV + 1 dose of bOPV (liquid dosage form/sugar pill). (2) To evaluate the safety of bOPV (liquid dosage form/sugar pill) vaccine.
100 Clinical Results associated with Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live(Institute of Medical Biology Chinese Academy of Medical Sciences)
100 Translational Medicine associated with Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live(Institute of Medical Biology Chinese Academy of Medical Sciences)
100 Patents (Medical) associated with Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live(Institute of Medical Biology Chinese Academy of Medical Sciences)
100 Deals associated with Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live(Institute of Medical Biology Chinese Academy of Medical Sciences)